BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 28124735)

  • 1. Disease burden and pain in obese cancer patients with chemotherapy-induced peripheral neuropathy.
    Cox-Martin E; Trahan LH; Cox MG; Dougherty PM; Lai EA; Novy DM
    Support Care Cancer; 2017 Jun; 25(6):1873-1879. PubMed ID: 28124735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Painful and non-painful chemotherapy-induced peripheral neuropathy and quality of life in colorectal cancer survivors: results from the population-based PROFILES registry.
    Bonhof CS; Trompetter HR; Vreugdenhil G; van de Poll-Franse LV; Mols F
    Support Care Cancer; 2020 Dec; 28(12):5933-5941. PubMed ID: 32281032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age-related differences in patient-reported and objective measures of chemotherapy-induced peripheral neuropathy among cancer survivors.
    Wong ML; Cooper BA; Paul SM; Abrams G; Topp K; Kober KM; Chesney MA; Mazor M; Schumacher MA; Conley YP; Levine JD; Miaskowski C
    Support Care Cancer; 2019 Oct; 27(10):3905-3912. PubMed ID: 30770977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy-induced peripheral neuropathy in the detroit research on cancer survivors (ROCS) cohort.
    Sreeram K; Seaton R; Greenwald MK; Kamgar M; Assad H; Baird T; Schwartz AG; Ruterbusch J; Simon MS
    Cancer Causes Control; 2023 May; 34(5):459-468. PubMed ID: 36934365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring the efficacy of an electronic symptom assessment and self-care intervention to preserve physical function in individuals receiving neurotoxic chemotherapy.
    Knoerl R; Weller E; Halpenny B; Berry D
    BMC Cancer; 2018 Dec; 18(1):1203. PubMed ID: 30514351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk.
    Bao T; Basal C; Seluzicki C; Li SQ; Seidman AD; Mao JJ
    Breast Cancer Res Treat; 2016 Sep; 159(2):327-33. PubMed ID: 27510185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy-Induced Peripheral Neurotoxicity in Cancer Survivors: Predictors of Long-Term Patient Outcomes.
    Battaglini E; Goldstein D; Grimison P; McCullough S; Mendoza-Jones P; Park SB
    J Natl Compr Canc Netw; 2021 Jul; 19(7):821-828. PubMed ID: 34340206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prevalence and pattern of chemotherapy-induced peripheral neuropathy among women with breast cancer receiving care in a large community oncology practice.
    Simon NB; Danso MA; Alberico TA; Basch E; Bennett AV
    Qual Life Res; 2017 Oct; 26(10):2763-2772. PubMed ID: 28664460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry.
    Beijers AJ; Mols F; Tjan-Heijnen VC; Faber CG; van de Poll-Franse LV; Vreugdenhil G
    Acta Oncol; 2015 Apr; 54(4):463-9. PubMed ID: 25417732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN).
    Schloss JM; Colosimo M; Airey C; Masci P; Linnane AW; Vitetta L
    Support Care Cancer; 2017 Jan; 25(1):195-204. PubMed ID: 27612466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and validation of the comprehensive assessment scale for chemotherapy-induced peripheral neuropathy in survivors of cancer.
    Kanda K; Fujimoto K; Mochizuki R; Ishida K; Lee B
    BMC Cancer; 2019 Sep; 19(1):904. PubMed ID: 31506070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health-Related Quality of Life in Cancer Survivors with Chemotherapy-Induced Peripheral Neuropathy: A Randomized Clinical Trial.
    Bao T; Baser R; Chen C; Weitzman M; Zhang YL; Seluzicki C; Li QS; Piulson L; Zhi WI
    Oncologist; 2021 Nov; 26(11):e2070-e2078. PubMed ID: 34390283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy-induced peripheral neuropathy in African American cancer survivors: Risk factors and quality of life outcomes.
    Trendowski MR; Lusk CM; Ruterbusch JJ; Seaton R; Simon MS; Greenwald MK; Harper FWK; Beebe-Dimmer JL; Schwartz AG
    Cancer Med; 2021 Nov; 10(22):8151-8161. PubMed ID: 34687150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of obesity on neuropathy outcomes for paclitaxel- and oxaliplatin-treated cancer survivors.
    Timmins HC; Li T; Goldstein D; Trinh T; Mizrahi D; Harrison M; Horvath LG; Friedlander M; Kiernan MC; Park SB
    J Cancer Surviv; 2022 Apr; 16(2):223-232. PubMed ID: 33641031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Motor disorders related to oxaliplatin-induced peripheral neuropathy: long-term severity and impact on quality of life.
    Balayssac D; Kerckhove N; Selvy M; Pereira B; Gonneau C; Pétorin C; Vimal-Baguet A; Melnikov S; Kullab S; Hebbar M; Bouché O; Slimano F; Bourgeois V; Lebrun-Ly V; Thuillier F; Mazard T; Tavan D; Benmammar KE; Monange B; Ramdani M; Péré-Vergé D; Huet-Penz F; Bedjaoui A; Genty F; Leyronnas C; Pezet D; Martin V
    Support Care Cancer; 2024 Jun; 32(7):427. PubMed ID: 38869647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy-induced peripheral neuropathy in newly diagnosed breast cancer survivors treated with taxane: a prospective longitudinal study.
    Wang YJ; Chan YN; Jheng YW; Wu CJ; Lin MW; Tseng LM; Tsai YF; Liu LC
    Support Care Cancer; 2021 Jun; 29(6):2959-2971. PubMed ID: 33025227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy.
    Molassiotis A; Cheng HL; Leung KT; Li YC; Wong KH; Au JSK; Sundar R; Chan A; Ng TR; Suen LKP; Chan CW; Yorke J; Lopez V
    Brain Behav; 2019 Jun; 9(6):e01312. PubMed ID: 31063261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Somatic Yoga and Meditation on Fall Risk, Function, and Quality of Life for Chemotherapy-Induced Peripheral Neuropathy Syndrome in Cancer Survivors.
    Galantino ML; Tiger R; Brooks J; Jang S; Wilson K
    Integr Cancer Ther; 2019; 18():1534735419850627. PubMed ID: 31131640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence of slow and variable choice-stepping reaction time in cancer survivors with chemotherapy-induced peripheral neuropathy.
    Menant JC; Goldstein D; Au K; Trinh T; van Schooten KS; McCrary JM; Harris CA; Forster BC; Park SB
    Gait Posture; 2021 Sep; 89():178-185. PubMed ID: 34320441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Living with chemotherapy-induced peripheral neuropathy: Uncovering the symptom experience and self-management of neuropathic symptoms among cancer survivors.
    Chan CW; Cheng H; Au SK; Leung KT; Li YC; Wong KH; Molassiotis A
    Eur J Oncol Nurs; 2018 Oct; 36():135-141. PubMed ID: 30322504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.